CR7025A - Derivados biarilicos de nicotinamida de utilidad como inhibidores de isozimas pde4 - Google Patents
Derivados biarilicos de nicotinamida de utilidad como inhibidores de isozimas pde4Info
- Publication number
- CR7025A CR7025A CR7025A CR7025A CR7025A CR 7025 A CR7025 A CR 7025A CR 7025 A CR7025 A CR 7025A CR 7025 A CR7025 A CR 7025A CR 7025 A CR7025 A CR 7025A
- Authority
- CR
- Costa Rica
- Prior art keywords
- utility
- pde4
- inhibitors
- isozimas
- biarilic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
COMPUESTOS DE UTILIDAD COMO INHIBIDORES DE PDE4 EN TRATAMIENTO DE ENFERMEDADES REGULADAS POR LA ACTIVACION Y DESGRANULACION DE EOSINOFILOS, ESPECIALMENTE ASMA, BRONQUITIS CRONICA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26549201P | 2001-01-31 | 2001-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR7025A true CR7025A (es) | 2003-11-25 |
Family
ID=23010671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR7025A CR7025A (es) | 2001-01-31 | 2003-07-17 | Derivados biarilicos de nicotinamida de utilidad como inhibidores de isozimas pde4 |
Country Status (25)
Country | Link |
---|---|
US (2) | US6649633B2 (es) |
EP (1) | EP1355884A1 (es) |
JP (1) | JP2004520386A (es) |
KR (1) | KR20030074761A (es) |
CN (1) | CN1518542A (es) |
BG (1) | BG108038A (es) |
BR (1) | BR0116852A (es) |
CA (1) | CA2436535A1 (es) |
CR (1) | CR7025A (es) |
CZ (1) | CZ20031895A3 (es) |
EA (1) | EA200300621A1 (es) |
EC (2) | ECSP034710A (es) |
EE (1) | EE200300360A (es) |
HU (1) | HUP0400637A2 (es) |
IL (1) | IL156413A0 (es) |
IS (1) | IS6846A (es) |
MA (1) | MA26983A1 (es) |
MX (1) | MXPA03006887A (es) |
NO (1) | NO20033397L (es) |
NZ (1) | NZ526453A (es) |
OA (1) | OA12540A (es) |
PL (1) | PL364135A1 (es) |
SK (1) | SK8792003A3 (es) |
WO (1) | WO2002060875A1 (es) |
ZA (1) | ZA200304894B (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
ES2427930T3 (es) * | 2001-05-23 | 2013-11-04 | Mitsubishi Tanabe Pharma Corporation | Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos |
WO2002094321A1 (fr) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Compositions favorisant la guérison d'une fracture osseuse |
US6951869B2 (en) * | 2002-02-26 | 2005-10-04 | Schlesinger Stephen L | Use of leukotriene receptor antagonist for treatment of scarring |
EP1424101A3 (en) * | 2002-11-29 | 2004-08-18 | NOZAKI, Masako | Use of a leukotriene C4 and D4 receptor antagonist for the preparation of a medicament for treating or preventing brain inflammation and sepsis |
EP1594459B1 (en) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
WO2004087211A2 (en) * | 2003-04-01 | 2004-10-14 | Applied Research Systems Ars Holding N.V. | Inhibitors of phosphodiesterases in infertility |
GB0309781D0 (en) * | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
GB0317484D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
US20050020587A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
US7534894B2 (en) * | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US20050154006A1 (en) * | 2004-01-09 | 2005-07-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives |
WO2006073413A1 (en) * | 2004-02-20 | 2006-07-13 | The Board Of Trustees Of The University Of Illinois | Blood pressure reduction in salt-sensitive |
US20090253908A1 (en) * | 2004-03-11 | 2009-10-08 | Glaxo Group Limited | Novel m3 muscarinic acetylchoine receptor antagonists |
EP2172222A3 (en) * | 2004-04-26 | 2010-06-23 | Ono Pharmaceutical Co., Ltd. | Novel BLT2-mediated disease, BLT2-binding agent and compound |
US7704522B2 (en) * | 2004-09-08 | 2010-04-27 | Clyde Morgan | Topical medicament |
US8597947B2 (en) | 2004-12-29 | 2013-12-03 | Hadasit Medical Research Services & Development Limited | Undifferentiated stem cell culture systems |
EP2410044B1 (en) | 2004-12-29 | 2022-06-22 | Hadasit Medical Research Services And Development Ltd. | Stem cells culture systems |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
BRPI0618643A2 (pt) | 2005-11-09 | 2011-09-06 | Combinatorx Inc | composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
AU2008242106B2 (en) | 2007-04-18 | 2013-05-16 | Hadasit Medical Research Services And Development Ltd. | Stem cell-derived retinal pigment epithelial cells |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US8778621B2 (en) | 2009-05-12 | 2014-07-15 | Koninklijke Philips N.V. | Phosphodiesterase 4D7 as marker for malignant, hormone-sensitive prostate cancer |
EP2430191B1 (en) * | 2009-05-12 | 2018-09-19 | Koninklijke Philips N.V. | Phosphodiesterase 4d7 as prostate cancer marker |
USRE46608E1 (en) | 2009-09-01 | 2017-11-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
DK2473045T3 (en) | 2009-09-01 | 2016-12-12 | Catabasis Pharmaceuticals Inc | Niacin-FATTY ACID CONJUGATES AND THEIR USES |
US20110082210A1 (en) * | 2009-10-05 | 2011-04-07 | Milne Jill C | Fatty acid fibrate derivatives and their uses |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
CN105392777B (zh) * | 2013-06-27 | 2020-09-22 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
ES2694375T3 (es) * | 2013-09-17 | 2018-12-20 | Vectus Biosystems Limited | Composiciones para el tratamiento de la hipertensión y/o de la fibrosis |
WO2016108240A1 (en) | 2014-12-30 | 2016-07-07 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
SG11201705379VA (en) | 2014-12-30 | 2017-08-30 | Cell Cure Neurosciences Ltd | Rpe cell populations and methods of generating same |
ES2865024T3 (es) | 2015-07-29 | 2021-10-14 | Hadasit Med Res Service | Producción a gran escala de células de epitelio pigmentario retiniano |
CN108138145A (zh) | 2015-08-05 | 2018-06-08 | 细胞治疗神经科学有限公司 | 用于治疗视网膜疾病的光感受器的制备 |
CA2993912A1 (en) | 2015-08-05 | 2017-02-09 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
WO2017072763A1 (en) | 2015-10-26 | 2017-05-04 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
US9725406B1 (en) | 2016-10-13 | 2017-08-08 | Resolvex Pharmaceuticals Inc. | Substituted hydroxystilbenes and their therapeutic applications |
CA3056653A1 (en) | 2017-03-16 | 2018-09-20 | Bio Time, Inc. | Methods for the treatment of retinal diseases |
JP2021509110A (ja) | 2017-12-29 | 2021-03-18 | セル キュア ニューロサイエンシズ リミテッド | 網膜色素上皮細胞組成物 |
WO2019213570A1 (en) * | 2018-05-04 | 2019-11-07 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
CN113038951B (zh) | 2018-09-20 | 2024-04-30 | 耶达研究及发展有限公司 | 治疗肌萎缩侧索硬化的方法 |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
CN111888349B (zh) * | 2020-07-29 | 2021-10-22 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 印楝素在制备促进缺血超长随意皮瓣存活药物的作用 |
EP4351334A1 (en) | 2021-06-09 | 2024-04-17 | Lineage Cell Therapeutics, Inc. | Methods and compositions for treating retinal diseases and conditions |
KR20240038013A (ko) | 2021-07-28 | 2024-03-22 | 리니지 셀 테라퓨틱스, 인크. | 망막 색소 상피 세포의 확장 |
WO2023211857A1 (en) | 2022-04-25 | 2023-11-02 | Lineage Cell Therapeutics, Inc. | Methods and compositions for treating vision loss |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2140772A5 (en) | 1971-06-07 | 1973-01-19 | Aries Robert | Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics |
US4270946A (en) * | 1979-10-01 | 1981-06-02 | Stauffer Chemical Company | N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof |
US4692185A (en) * | 1986-01-13 | 1987-09-08 | Stauffer Chemical Company | N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides |
US4861891A (en) * | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
EP0500989B1 (en) | 1991-02-27 | 1998-12-09 | Lacer, S.A. | N-(alpha-substituted-pyridinyl) carbonyl dipeptide antihypertensive agents |
DE4200323A1 (de) | 1992-01-09 | 1993-07-15 | Bayer Ag | Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten |
HU225869B1 (en) | 1992-04-02 | 2007-11-28 | Smithkline Beecham Corp | Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them |
JPH08511805A (ja) | 1993-06-18 | 1996-12-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
JP3406689B2 (ja) | 1994-03-15 | 2003-05-12 | 株式会社大塚製薬工場 | ナフチリジン及びピリドピラジン誘導体 |
US5618027A (en) * | 1994-07-20 | 1997-04-08 | Nevrekar; Venkatesh R. | Gate valve |
WO1996019990A1 (en) | 1994-12-23 | 1996-07-04 | Smithkline Beecham Corporation | 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds |
TW429148B (en) * | 1995-10-27 | 2001-04-11 | Pfizer | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases |
GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US5922557A (en) | 1997-01-09 | 1999-07-13 | Merck & Co., Inc. | System for stably expressing a high-affinity camp phosphodiesterase and use thereof |
IL132033A0 (en) | 1997-04-04 | 2001-03-19 | Pfizer Prod Inc | Nicotinamide derivatives |
GB9715584D0 (en) * | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
UA67753C2 (uk) | 1997-10-10 | 2004-07-15 | Смітклайн Бічам Корпорейшн | Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот |
AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
MA24682A1 (fr) | 1997-10-23 | 1999-07-01 | Smithkline Beecham Corp | Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant |
EP1252157B1 (en) * | 2000-01-31 | 2004-06-23 | Pfizer Products Inc. | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
AU2700201A (en) * | 2000-01-31 | 2001-08-14 | Pfizer Products Inc. | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
-
2001
- 2001-12-06 CN CNA018230717A patent/CN1518542A/zh active Pending
- 2001-12-06 CA CA002436535A patent/CA2436535A1/en not_active Abandoned
- 2001-12-06 EP EP01273556A patent/EP1355884A1/en not_active Withdrawn
- 2001-12-06 SK SK879-2003A patent/SK8792003A3/sk not_active Application Discontinuation
- 2001-12-06 CZ CZ20031895A patent/CZ20031895A3/cs unknown
- 2001-12-06 WO PCT/IB2001/002341 patent/WO2002060875A1/en not_active Application Discontinuation
- 2001-12-06 HU HU0400637A patent/HUP0400637A2/hu unknown
- 2001-12-06 EE EEP200300360A patent/EE200300360A/xx unknown
- 2001-12-06 BR BR0116852-5A patent/BR0116852A/pt not_active IP Right Cessation
- 2001-12-06 OA OA1200300175A patent/OA12540A/en unknown
- 2001-12-06 IL IL15641301A patent/IL156413A0/xx unknown
- 2001-12-06 EA EA200300621A patent/EA200300621A1/ru unknown
- 2001-12-06 JP JP2002561026A patent/JP2004520386A/ja active Pending
- 2001-12-06 KR KR10-2003-7010074A patent/KR20030074761A/ko not_active Application Discontinuation
- 2001-12-06 MX MXPA03006887A patent/MXPA03006887A/es not_active Application Discontinuation
- 2001-12-06 NZ NZ526453A patent/NZ526453A/en unknown
- 2001-12-06 PL PL01364135A patent/PL364135A1/xx not_active Application Discontinuation
-
2002
- 2002-01-31 US US10/062,813 patent/US6649633B2/en not_active Expired - Fee Related
-
2003
- 2003-06-16 IS IS6846A patent/IS6846A/is unknown
- 2003-06-24 ZA ZA200304894A patent/ZA200304894B/en unknown
- 2003-07-02 US US10/613,988 patent/US6953810B2/en not_active Expired - Fee Related
- 2003-07-17 CR CR7025A patent/CR7025A/es not_active Application Discontinuation
- 2003-07-21 MA MA27241A patent/MA26983A1/fr unknown
- 2003-07-28 BG BG108038A patent/BG108038A/xx unknown
- 2003-07-30 NO NO20033397A patent/NO20033397L/no not_active Application Discontinuation
- 2003-07-31 EC EC2003004710A patent/ECSP034710A/es unknown
- 2003-07-31 EC EC2003004709A patent/ECSP034709A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP034709A (es) | 2003-09-24 |
IS6846A (is) | 2003-06-16 |
CN1518542A (zh) | 2004-08-04 |
CA2436535A1 (en) | 2002-08-08 |
NO20033397D0 (no) | 2003-07-30 |
WO2002060875A8 (en) | 2003-07-31 |
MXPA03006887A (es) | 2003-11-13 |
EA200300621A1 (ru) | 2003-12-25 |
KR20030074761A (ko) | 2003-09-19 |
WO2002060875A1 (en) | 2002-08-08 |
US6953810B2 (en) | 2005-10-11 |
NZ526453A (en) | 2005-01-28 |
OA12540A (en) | 2006-06-05 |
BR0116852A (pt) | 2004-02-25 |
MA26983A1 (fr) | 2004-12-20 |
CZ20031895A3 (cs) | 2004-08-18 |
IL156413A0 (en) | 2004-01-04 |
ZA200304894B (en) | 2004-06-24 |
EE200300360A (et) | 2003-12-15 |
US20040048903A1 (en) | 2004-03-11 |
US6649633B2 (en) | 2003-11-18 |
EP1355884A1 (en) | 2003-10-29 |
HUP0400637A2 (hu) | 2004-06-28 |
PL364135A1 (en) | 2004-12-13 |
SK8792003A3 (en) | 2004-09-08 |
ECSP034710A (es) | 2003-09-24 |
BG108038A (en) | 2004-07-30 |
JP2004520386A (ja) | 2004-07-08 |
US20020193612A1 (en) | 2002-12-19 |
NO20033397L (no) | 2003-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR7025A (es) | Derivados biarilicos de nicotinamida de utilidad como inhibidores de isozimas pde4 | |
CR7043A (es) | Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4 | |
UY26569A1 (es) | Derivados de nicotinamida benzocondensada - heterocíclilo útiles como inhibidores selectivos de las isozimas pde4 | |
NL300933I2 (nl) | Letermovir | |
CR7038A (es) | Derivados amida de acido tiazolilico, oxazolilico, pirrolilico e imidiazolilico utiles como inhibidores de las isozimas pde4 | |
WO2007041130A3 (en) | Deazapurines useful as inhibitors of janus kinases | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
HRP20050318A2 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes | |
WO2005028475A3 (en) | Compositions useful as inhibitors of protein kinases | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
WO2005056547A3 (en) | Quinoxalines useful as inhibitors of protein kinases | |
NO20063572L (no) | Kinazolinditosylatsalt forbindelser | |
IS2520B (is) | Nikótínamíð afleiður nytsamlegar sem P38 hindrar | |
WO2004022537A3 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
WO2005063734A3 (de) | Substituierte thiophene | |
NO20074431L (no) | Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer | |
HK1096392A1 (en) | Substituted heterocycles | |
ATE408601T1 (de) | Fredericamycin-derivate | |
DE602005015319D1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen | |
WO2007015923A8 (en) | Benzimidazoles useful as inhibitors of protein kinases | |
ATE549024T1 (de) | Chinazolin-kaliumkanalhemmer | |
CY1112568T1 (el) | Χρηση των πυριμιδυλαμινοβενζαμιδων για τη θεραπεια των νοσων που ανταποκρινονται στην ρυθμιση της δρασης της τιε-2 κινασης | |
DE602007011756D1 (de) | Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |